Recent Quotes
My Watchlist
Indicators
OGJ 150 Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

784.54 +23.09 (+3.03%)
Streaming Delayed Price Updated: 3:30 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
58 59 Next >
News headline image
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts ↗
 
Via Benzinga
News headline image
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
News headline image
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
These stocks are used to beating the market. 
Via The Motley Fool
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading
Via Investor Brand Network
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
News headline image
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
2 Top Growth Stocks to Buy With $1,000 Right Now ↗
Even a modest starting investment in the right stocks could pay off in the years ahead. 
Via The Motley Fool
News headline image
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗
There's room for multiple winners in the fast-growing weight-loss market. 
Via The Motley Fool
News headline image
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. 
Via Benzinga
News headline image
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Stock-Split Watch: Could These 2 Market-Beaters Be Next? ↗
Investors might continue bidding up shares of these companies regardless. 
Via The Motley Fool
News headline image
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? ↗
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. 
Via Benzinga
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. 
Via Benzinga
News headline image
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High ↗
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products. 
Via Investor's Business Daily
News headline image
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
News headline image
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>